VISTA, Calif.--(BUSINESS WIRE)--Aperio, the global leader in providing digital pathology solutions that improve patient care, today announced that David Schlotterbeck, former Chairman and CEO of CareFusion, has been appointed to its Board of Directors.
“Dave has considerable operational experience building and leading successful organizations that sell innovative technology-based solutions to hospitals and other healthcare institutions,” said Dirk G. Soenksen, Chairman and CEO of Aperio. “Given the rapid emergence of the digital pathology market, including growing interest from pathologists and hospitals, we are excited to add Dave’s expertise to our board at this important time. Over 500 Aperio systems are being used in hospitals and reference labs today, and while this makes us by far the leader, it’s clear that we are only scratching the surface. Dave represents another impactful and highly leverageable addition to our leadership team that will help drive growth.”
Mr. Schlotterbeck recently served as Chairman and CEO of CareFusion, a leading medical technology company. Previously, he was Vice Chairman of Cardinal Health and CEO of its Clinical and Medical Products business segment. He joined Cardinal Health through the acquisition of Alaris Medical Systems, where he served as President and CEO from 1999 through 2004. Mr. Schlotterbeck previously held senior executive leadership positions with Pacific Scientific Company; Vitalcom, Inc.; and Nellcor, Inc.
“It’s clear that digital pathology is much bigger than whole slide imaging and viewing, and that digital pathology will have a significant impact on patient care and personalized medicine,” commented Dave Schlotterbeck. “I’m pleased to be on the Aperio board, and look forward to helping the Company solidify its global leadership position.”
The addition of Dave Schlotterbeck complements the recent addition of several healthcare executives to Aperio’s leadership team, including Keith Hagen as Chief Operating Officer, Jared Schwartz, MD, PhD, as Chief Medical Officer, Patrick Yount as Chief Financial Officer, and Steven Russell as General Manager of Healthcare.
Other Aperio Board members include Chairman and CEO Dirk Soenksen; Martin Felsenthal, Partner at HLM Venture Partners; Mark Gergen, Senior Vice President of corporate development at Amylin Pharmaceuticals; Tom Rodgers, Partner at Advanced Technology Ventures (ATV); and Zubeen Schroff, Partner at Galen Partners.
About Aperio
Aperio is the leading provider of digital pathology solutions in hospitals, reference labs, and pharmaceutical and research institutions across the world. Today, our affordable and complete product portfolio improves patient care by enhancing quality assurance, delivering more efficient workflows, facilitating access to new and more targeted therapies, and improving pathologists’ skills via lifelong education. Our comprehensive product line features our ScanScope® scanners, Spectrum™ image management (PACS) software, SecondSlide® consultation network for pathology, and image analysis tools and services. Aperio’s products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For clearance updates and more information please visit www.aperio.com.